Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 212

1.

Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.

Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, Konstan MW, Moss R, Retsch-Bogart G, Wagener J, Waltz D, Wilmott R, Zeitlin PL, Ramsey B; Cystic Fibrosis Therapeutics Development Network Study Group.

Am J Respir Crit Care Med. 2003 Mar 15;167(6):841-9. Epub 2002 Dec 12.

PMID:
12480612
2.

Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study.

Master V, Roberts GW, Coulthard KP, Baghurst PA, Martin A, Roberts ME, Onishko CR, Martin AJ, Linke RJ, Holmes M, Jarvinen A, Kennedy D, Colebatch KA, Hansman D, Parsons DW.

Pediatr Pulmonol. 2001 May;31(5):367-76.

PMID:
11340683
3.

Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.

Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev-K M, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith AL.

N Engl J Med. 1999 Jan 7;340(1):23-30.

4.

Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis.

Wiesemann HG, Steinkamp G, Ratjen F, Bauernfeind A, Przyklenk B, Döring G, von der Hardt H.

Pediatr Pulmonol. 1998 Feb;25(2):88-92.

PMID:
9516091
5.

Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis.

Gibson RL, Emerson J, Mayer-Hamblett N, Burns JL, McNamara S, Accurso FJ, Konstan MW, Chatfield BA, Retsch-Bogart G, Waltz DA, Acton J, Zeitlin P, Hiatt P, Moss R, Williams J, Ramsey BW.

Pediatr Pulmonol. 2007 Jul;42(7):610-23.

PMID:
17534969
6.

Long-term benefits of inhaled tobramycin in children with cystic fibrosis: first clinical observations from Poland.

Stelmach I, Korzeniewska A, Stelmach W.

Respiration. 2008;75(2):178-81. Epub 2007 Apr 13.

PMID:
17435382
7.

Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial.

Konstan MW, Geller DE, Minić P, Brockhaus F, Zhang J, Angyalosi G.

Pediatr Pulmonol. 2011 Mar;46(3):230-8. doi: 10.1002/ppul.21356. Epub 2010 Oct 20.

8.

Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa.

Drobnic ME, Suñé P, Montoro JB, Ferrer A, Orriols R.

Ann Pharmacother. 2005 Jan;39(1):39-44. Epub 2004 Nov 23.

PMID:
15562142
9.

Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection.

Trapnell BC, McColley SA, Kissner DG, Rolfe MW, Rosen JM, McKevitt M, Moorehead L, Montgomery AB, Geller DE; Phase 2 FTI Study Group.

Am J Respir Crit Care Med. 2012 Jan 15;185(2):171-8. doi: 10.1164/rccm.201105-0924OC. Epub 2011 Nov 17.

10.

Long-term tobramycin aerosol therapy of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.

Gappa M, Steinkamp G, Tümmler B, von der Hardt H.

Scand J Gastroenterol Suppl. 1988;143:74-6.

PMID:
3164515
11.

Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis.

Burns JL, Van Dalfsen JM, Shawar RM, Otto KL, Garber RL, Quan JM, Montgomery AB, Albers GM, Ramsey BW, Smith AL.

J Infect Dis. 1999 May;179(5):1190-6.

PMID:
10191222
12.

Long-term tobramycin aerosol therapy in cystic fibrosis.

Steinkamp G, Tümmler B, Gappa M, Albus A, Potel J, Döring G, von der Hardt H.

Pediatr Pulmonol. 1989;6(2):91-8.

PMID:
2494640
13.

Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection.

Milla CE, Chmiel JF, Accurso FJ, VanDevanter DR, Konstan MW, Yarranton G, Geller DE; KB001 Study Group.

Pediatr Pulmonol. 2014 Jul;49(7):650-8. doi: 10.1002/ppul.22890. Epub 2013 Sep 9.

14.

Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.

Al-Aloul M, Nazareth D, Walshaw M.

J Aerosol Med Pulm Drug Deliv. 2014 Aug;27(4):299-305. doi: 10.1089/jamp.2013.1055. Epub 2013 Nov 12.

PMID:
24219814
15.

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.

Konstan MW, Flume PA, Kappler M, Chiron R, Higgins M, Brockhaus F, Zhang J, Angyalosi G, He E, Geller DE.

J Cyst Fibros. 2011 Jan;10(1):54-61. doi: 10.1016/j.jcf.2010.10.003. Epub 2010 Nov 12.

16.

Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients.

Mulheran M, Hyman-Taylor P, Tan KH, Lewis S, Stableforth D, Knox A, Smyth A.

Antimicrob Agents Chemother. 2006 Jul;50(7):2293-9.

17.

Tobramycin inhalation powder in cystic fibrosis patients: response by age group.

Geller DE, Nasr SZ, Piggott S, He E, Angyalosi G, Higgins M.

Respir Care. 2014 Mar;59(3):388-98. doi: 10.4187/respcare.02264. Epub 2013 Aug 27.

18.
19.

Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.

Geller DE, Konstan MW, Smith J, Noonberg SB, Conrad C.

Pediatr Pulmonol. 2007 Apr;42(4):307-13.

PMID:
17352404
20.

Safety of inhaled (Tobi®) and intravenous tobramycin in young children with cystic fibrosis.

Hennig S, McKay K, Vidmar S, O'Brien K, Stacey S, Cheney J, Wainwright CE.

J Cyst Fibros. 2014 Jul;13(4):428-34. doi: 10.1016/j.jcf.2014.01.014. Epub 2014 Feb 22.

Supplemental Content

Support Center